Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: Effects of differing forms of hormonal contraception

European Journal of Haematology

Volumn 70, Issue 5, 2003, Pages 310-314

  Yoong, Wai C ^a,c   Tuck, S M ^a   Pasi, K J ^b   Owens, D ^b   Perry, D J ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Activation markers; Combined oral contraceptive pill; Hormonal contraception; Sickle cell disease

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIGEN; BETA THROMBOGLOBULIN; ORAL CONTRACEPTIVE AGENT; PROTEIN S; PROTHROMBIN; THROMBOCYTE FACTOR 4;

ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG SAFETY; DRUG SCREENING; FEMALE; FIBRINOLYSIS; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HORMONAL CONTRACEPTION; HUMAN; PHLEBOTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; TEACHING HOSPITAL; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; FIBRINOLYSIS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; PLATELET ACTIVATION; RISK FACTORS; SAFETY; THROMBIN; THROMBOEMBOLISM;

EID: 0037880584     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.00061.x     Document Type: Article

References (23)

1. HOWARD RJ, LILLIS C, TUCK SM. Contraception, counselling and pregnancy in women with sickle cell disease. Br Med J 1995;306:1735-1737.
2. HOWARD RJ, TUCK SM, PEARSON TC. Pregnancy in sickle cell disease in the UK: multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol 1995;102:947-951.
3. SPITZER WO, LEWIS MA, HEINEMANN AJ, THOROGOOD M, MACRAE KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case control study. Br Med J 1996;312:83-88.
4. FRANCIS RB. Protein S deficiency in sickle cell anaemia. J Lab Clin Med 1988;May:571-576.
5. NAGEL RL, FABRY ME. Evolution of laboratory parameters during sickle cell painful crises: evidence compatible with dense red cell sequestration without thrombosis. Am J Med Sci 1988;296:293-298.
6. KURANTSIN-MILLS J, OFUSU FA, SAFA TK, SIEGEL RS, LESSIN LS. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haem 1992;81:539-544.
7. APBI Data Sheet Compendium 2001-2. Data Pharm Publication Ltd, London.
8. GREENWALD JG. Stroke in a woman with sickle cell trait taking oral contraceptives. Conn Med 1971;35:231-232.
9. HARGUS EP, SHEARN R, COLON AR. Pulmonary embolism in a female adolescent with sickle cell trait and oral contraceptive use. Am J Obstet Gynecol 1977;129:692.
10. Task Force on Oral Contraceptives. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991;98:1117-1128.
11. CAMPBELL SJ, MACKIE IJ, ROBINSON GE, MACHIN SJ. Contact factor mediated fibrinolysis is increased by the combined oral contraceptive pill. Br J Obstet Gynaecol 1992;100:79-84.
12. WATSON WE, KRISHNAMURTHI S, MARKS G, ELLIS V, SCULLY MF, WHITE JM, KAKKAR VV. Platelet activation during steady state sickle cell disease. J Med 1983;14:17-36.
13. EL HAZMI MAF, WARSY AS, BAHAKIM H. Blood Proteins C and S in sickle cell disease. Acta Haematol 1993;90:114-119.
14. KLUET C, LANSIK M. Effect of oral contraceptives on haemostatic variables. Thromb Haemostas 1997;78:315-326.
15. MURDOCK PJ, BROOKS S, MELLARS G, CHEUNG G, JACOB D, OWENS D, PARMAR M, RIDDEL A. A simple monoclonal antibody based ELISA for tree Protein S. Comparison with PEG precipitation. Clin Lab Haem 1997;19:111-114.
16. FARMER RDT, LAWRENSON RA, THOMPSON CR, KENNEDY JG, HAMBLETON IR. Population based study of risk of venous thromboembolism associated with various oral contraceptive. Lancet 1997;349:83-88.
17. QUEHENBERGER P, LONER U, KAPIOTIS S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during the use of oral contraceptives. Thromb Haemostas 1996;76:729-734.
18. NOTELOVITZ M, KITCHENS CS, KHAN FY. Changes in coagulation and anticoagulation in women taking low dose triphasic oral contraceptives: a controlled comparative 12 month clinical trial. Am J Obstet Gynecol 1992;176:1258-1261.
19. KUHL H. Effects of progestogens on hemostasis. Maturitas 1996;24:1-19.
20. WINKLER UH. Hemostasis in oral contraception: the role of progestogens. Gynecol Endocrmol 1993;7(Suppl.):59-64.
21. GREEN D, SCOTT JP. Is sickle cell disease a thrombotic event? Am J Hematol 1986;23:317-321.
22. LUTCHER CL. Blood coagulation studies and the effect of oral contraceptives in patients with SCA. Clin Res 1976;24:47A(Abstract).
23. FOTHERBY K. Levonorgestrel: clinical pharmacokinetics. Clin Pharmacokin 1995;28:203-215.